China National Pharmaceutical Group Corporation, a wholly-owned subsidiary of the company, has obtained the "Drug Registration Certificate" for the injection of chloroquine phosphate.

China National Pharmaceutical Group Corp (Sinopharm) recently announced that its wholly-owned subsidiary, Sinopharm Industrial, has received the Drug Registration Certificate for Ketamine Hydrochloride Injection issued by the National Medical Products Administration. The specification is 2ml:0.1g, and the registration category is Class 3 chemical drugs. Sinopharm Industrial is the first enterprise to pass the consistency evaluation. Up to now, the project has accumulated research and development investment of approximately 6.8311 million yuan. This will enrich the company's anesthesia and analgesia product portfolio, enhance competitiveness, but have no significant impact on current operating performance, and there is uncertainty in drug sales.